As a consequence of the COVID-19 pandemic caused by SARS-CoV-2 coronavirus and its variants, for the last 2 years, Stratech has allocated many of its resources and efforts on helping the fight against the disease. We are working relentlessly toward sourcing and providing specific reagents for basic research as well as for assay, vaccine, and drug development.

As part of our comprehensive infectious disease portfolio, Stratech can offer a complete range of SARS-CoV-2 proteins, antibodies, ELISA, LFA and qPCR based assays and many other accessory and complimentary products to help studying SARS-CoV-2.

Select below the COVID-19 product category of your interest